Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial.

Royal Infirmary of Edinburgh, Edinburgh, UK.
Gut (Impact Factor: 13.32). 11/2003; 52(10):1479-86.
Source: PubMed

ABSTRACT N-3 fatty acids, especially eicosapentaenoic acid (EPA), may possess anticachectic properties. This trial compared a protein and energy dense supplement enriched with n-3 fatty acids and antioxidants (experimental: E) with an isocaloric isonitrogenous control supplement (C) for their effects on weight, lean body mass (LBM), dietary intake, and quality of life in cachectic patients with advanced pancreatic cancer.
A total of 200 patients (95 E; 105 C) were randomised to consume two cans/day of the E or C supplement (480 ml, 620 kcal, 32 g protein +/- 2.2 g EPA) for eight weeks in a multicentre, randomised, double blind trial.
At enrolment, patients' mean rate of weight loss was 3.3 kg/month. Intake of the supplements (E or C) was below the recommended dose (2 cans/day) and averaged 1.4 cans/day. Over eight weeks, patients in both groups stopped losing weight (delta weight E: -0.25 kg/month versus C: -0.37 kg/month; p = 0.74) and LBM (Delta LBM E: +0.27 kg/month versus C: +0.12 kg/month; p = 0.88) to an equal degree (change from baseline E and C, p<0.001). In view of evident non-compliance in both E and C groups, correlation analyses were undertaken to examine for potential dose-response relationships. E patients demonstrated significant correlations between their supplement intake and weight gain (r = 0.50, p<0.001) and increase in LBM (r = 0.33, p = 0.036). Such correlations were not statistically significant in C patients. The relationship of supplement intake with change in LBM was significantly different between E and C patients (p = 0.043). Increased plasma EPA levels in the E group were associated with weight and LBM gain (r = 0.50, p<0.001; r = 0.51, p = 0.001). Weight gain was associated with improved quality of life (p<0.01) only in the E group.
Intention to treat group comparisons indicated that at the mean dose taken, enrichment with n-3 fatty acids did not provide a therapeutic advantage and that both supplements were equally effective in arresting weight loss. Post hoc dose-response analysis suggests that if taken in sufficient quantity, only the n-3 fatty acid enriched energy and protein dense supplement results in net gain of weight, lean tissue, and improved quality of life. Further trials are required to examine the potential role of n-3 enriched supplements in the treatment of cancer cachexia.


Available from: Dirk J Gouma, Jun 03, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Muscle mass, intermuscular adipose tissue, and strength are important indicators of physical function. Dietary fatty acids (FAs) have been associated with muscle parameters such as larger size and higher strength, but large, population-based longitudinal data in older adults who are at risk of functional decline are lacking.
    Journal of Nutrition 10/2014; DOI:10.3945/jn.114.200337 · 4.23 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: It is estimated that half of all patients with cancer eventually develop a syndrome of cachexia, with anorexia and a progressive loss of adipose tissue and skeletal muscle mass. Cancer cachexia is characterized by systemic inflammation, negative protein and energy balance, and an involuntary loss of lean body mass. It is an insidious syndrome that not only has a dramatic impact on patient quality of life, but also is associated with poor responses to chemotherapy and decreased survival. Cachexia is still largely an underestimated and untreated condition, despite the fact that multiple mechanisms are reported to be involved in its development, with a number of cytokines postulated to play a role in the etiology of the persistent catabolic state. Existing therapies for cachexia, including orexigenic appetite stimulants, focus on palliation of symptoms and reduction of the distress of patients and families rather than prolongation of life. Recent therapies for the cachectic syndrome involve a multidisciplinary approach. Combination therapy with diet modification and/or exercise has been added to novel pharmaceutical agents, such as Megestrol acetate, medroxyprogesterone, ghrelin, omega-3-fatty acid among others. These agents are reported to have improved survival rates as well as quality of life. In this review, we will discuss the emerging understanding of the mechanisms of cancer cachexia, the current treatment options including multidisciplinary combination therapies, as well an update on new and ongoing clinical trials.
    04/2015; 7(4):17-29. DOI:10.4251/wjgo.v7.i4.17
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Although some studies have shown positive effects of omega-3 fattyacid supplementation on nutritional status of cancer patients undergoing differenttreatments, there is no consistency in results. The aim of this study was to examinethe effects of omega-3 fatty acid on the nutritional status of gastric cancer patientsduring the course of chemotherapy. Methods: In a double-blind clinical trial, 30 adult patients with gastric cancerreceiving chemotherapy were randomized into a supplement and a placebo groupsand given daily, for 6 weeks, a 3-g omega-3 fatty acid supplement (containing 1.8geicosapentaeonic plus 1.2g docosahexaenoic acid) and oral paraffin, respectively.Anthropometric data was collected and nutritional status assessed at the beginning,at week 4 and at the end of week 6. The data were analyzed using repeatedmeasures ANOVA and independent sample t-test. Results: The findings indicated that omega-3 fatty acid supplementation increasedbody weight, mean daily intake of energy and macronutrients, serum levels oftransferrin and albumin at the end of the 6-week period significantly (p<0.05). Allthese variables decreased in the placebo group (p<0.05). The increases in bodyweight, energy and carbohydrate intakes, and serum levels of albumin in thesupplement group were time-dependent (p<0.05). Conclusion: The results of present study showed that omega-3 fatty acidsupplementation can improve nutritional status in patients with gastric cancerduring the course of chemotherapy. We recommend using omega-3 fatty acidsupplement in patients with gastric cancer during chemotherapy.